How much funding has ENA Respiratory raised?

ENA Respiratory has raised $162.4M in total funding, most recently a Series A round.

When was ENA Respiratory founded?

ENA Respiratory was founded in 2020.

Where is ENA Respiratory headquartered?

ENA Respiratory is headquartered in Melbourne, United Kingdom.

What industry is ENA Respiratory in?

ENA Respiratory operates in Biotech, Healthcare.

How many employees does ENA Respiratory have?

ENA Respiratory has 1-10 employees.

ENA Respiratory

Q: Who are ENA Respiratory's investors?

ENA Respiratory's investors include Brandon Capital Partners, Bill & Melinda Gates Foundation, Uniseed, Minderoo Foundation.

Minimising the Impact of Viral Respiratory Infections

Melbourne, United Kingdom · Founded 2020 · $162.4M raised

Biotech

Healthcare

Headquarters: Melbourne
Employees: 1–10
Founded: 2020
Business Model: B2B

Website: enarespiratory.com
Total Funding: $162.4M
Last Round: $114.0M Series AJun 2026
Rounds: 3

About

ENA Respiratory is a clinical-stage pharmaceutical company developing antiviral host defense enhancers for the prevention of severe complications from respiratory viral infections. Its lead product, INNA-051, is a first-in-class TLR2/6 agonist delivered as a self-administered nasal product with a weekly dosing regimen, currently in Phase II clinical trials. The company is headquartered in Melbourne, Australia, and was formed in 2020 as a spin-off from ENA Therapeutics Pty Ltd (now Axelia Oncology).

Summary

ENA Respiratory is a Biotech company based in Melbourne, United Kingdom, founded in 2020. It has raised $162.4M in total across 3 rounds, most recently a $114.0M Series A round in Jun 2026. Investors include Brandon Capital Partners, Bill & Melinda Gates Foundation and Uniseed.

LinkedIn X (Twitter)